EGFR has been identified as a therapeutical target of an antisense plasmid DNA (EGFR-AS) for the treatment of head and neck squamous cell carcinoma (HNSCC) [87,88]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.